Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-04-09
DOI
10.1002/ajh.25488
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management
- (2018) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases
- (2018) Mrinal M. Patnaik et al. LEUKEMIA
- Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates
- (2018) Katherine Hoversten et al. LEUKEMIA & LYMPHOMA
- Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
- (2018) Matthieu Duchmann et al. EBioMedicine
- A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
- (2017) V Santini et al. LEUKEMIA
- DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
- (2016) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management
- (2016) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
- (2016) C. Elena et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes
- (2016) Prashant Sharma et al. LEUKEMIA & LYMPHOMA
- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
- (2016) Jane Merlevede et al. Nature Communications
- Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
- (2016) M M Patnaik et al. Blood Cancer Journal
- Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
- (2016) M M Patnaik et al. Blood Cancer Journal
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
- (2015) M. R. Savona et al. BLOOD
- Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome
- (2015) Vikas Madan et al. Nature Communications
- Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study
- (2014) Emnet A. Wassie et al. AMERICAN JOURNAL OF HEMATOLOGY
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
- (2014) M M Patnaik et al. LEUKEMIA
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
- (2013) Raphaël Itzykson et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
- (2013) M M Patnaik et al. LEUKEMIA
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More